Mendus AB (CHIX:IMMUS) Cyclically Adjusted PS Ratio: (As of Jul. 15, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CHIX:IMMUS Mendus AB CHIX:IMMUS
28 GF Score
Price kr32.70
! 2 Warning Signs
View Full Analysis

What is Mendus AB Cyclically Adjusted PS Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Mendus AB  (CHIX:IMMUs) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Mendus AB Cyclically Adjusted PS Ratio Related Terms


Mendus AB Cyclically Adjusted PS Ratio Historical Data

* Premium members only.

The historical data trend for Mendus AB's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Mendus AB Cyclically Adjusted PS Ratio Chart

Mendus AB Annual Data
Trend Jun16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 427.84 0.00 0.00 0.00

Mendus AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

CHIX:IMMUS vs VRTX, REGN, ALNY: Cyclically Adjusted PS Ratio Comparison

For the Biotechnology subindustry, Mendus AB's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Mendus AB Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Mendus AB's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Mendus AB's Cyclically Adjusted PS Ratio falls into.


CHIX:IMMUS
28GF Score
Mendus AB CHIX:IMMUS
Cyclically Adjusted PS Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Mendus AB Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Mendus AB's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 is calculated as:

For example, Mendus AB's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=0/133.5600*133.5600
=0.000

Current CPI (Mar. 2026) = 133.5600.

Mendus AB Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 0.000 101.019 0.000
201609 0.000 101.138 0.000
201612 0.000 102.022 0.000
201703 0.000 102.022 0.000
201706 0.000 102.752 0.000
201709 0.000 103.279 0.000
201712 0.000 103.793 0.000
201803 0.000 103.962 0.000
201806 0.000 104.875 0.000
201809 0.000 105.679 0.000
201812 0.000 105.912 0.000
201903 0.000 105.886 0.000
201906 0.000 106.742 0.000
201909 0.000 107.214 0.000
201912 0.000 107.766 0.000
202003 0.000 106.563 0.000
202006 0.000 107.498 0.000
202009 0.000 107.635 0.000
202012 0.000 108.296 0.000
202103 0.000 108.360 0.000
202106 0.000 108.928 0.000
202109 0.000 110.338 0.000
202112 0.000 112.486 0.000
202203 0.168 114.825 0.195
202206 0.000 118.384 0.000
202209 0.000 122.296 0.000
202212 -0.133 126.365 -0.141
202303 0.000 127.042 0.000
202306 0.000 129.407 0.000
202309 0.000 130.224 0.000
202312 0.000 131.912 0.000
202403 0.000 132.205 0.000
202406 0.000 132.716 0.000
202409 0.000 132.304 0.000
202412 0.000 132.987 0.000
202503 0.000 132.825 0.000
202506 0.000 133.699 0.000
202509 0.000 133.480 0.000
202512 0.000 133.390 0.000
202603 0.000 133.560 0.000

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Mendus AB Business Description

Other Exchanges IMMU:Sweden1YG0:Germany
Address Vastra Tradgardsgatan 15, Stockholm, SWE, 11153
Mendus AB is a clinical-level biopharmaceutical company based on the company's allogeneic dendritic cell biology focused on the development of immunotherapies that address tumor recurrence and hard-to-treat established tumors. Its operations consist of research and development for pharmaceuticals. The company's Pipeline includes: Vididencel, and Ilixadencel.
28GF Score

Get the complete analysis for CHIX:IMMUS

Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr32.70
Price